Bod Science (ASX:BOD) sold its rights to three intellectual properties to Optimus Salvus, according to a Jan. 24 filing with the Australian bourse.
The assets pertain to the rights to soft gel/S3 clinical research and data, Aqua Phase, and CLIC Protein, per the filing. The transaction consideration comprises a lump sum payment of AU$125,000 exclusive of tax, the forgiveness of debt claimed by the Aqua Phase inventors worth 2 million pounds sterling, and a 5% equity interest in Optimus Salvus.
Proceeds will form part of a deed fund and be transferred to Bod Science's creditors' trust in line with its deed of company arrangement, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.